

# Descriptive Characteristics of Angioedema Case Series with Abatacept (N=83)



Age, years, median (range), n=71	59 (16-83)
Cases reporting patients age <18 years, n	1
Abatacept indication, n (%)	
Rheumatoid arthritis	61 (73.5)
Arthritis	2 (2.4)
Spondyloarthritis	1 (1.2)
Arthralgia	1 (1.2)
Not reported	18 (21.7)
Year reported to FDA, n (%)	
2006-2008	12 (15.7)
2009-2011	8 (9.6)
2012-2014	22 (26.5)
2015-2017	25 (30.1)
2018-2019	15 (18.1)
Country, n (%)	
United States	61 (73.5)
Foreign	22 (26.5)



# Descriptive Characteristics of Angioedema Case Series with Abatacept (N=83)

Time to onset of angioedema from most recent abatacept exposure, n (%)	
Acute onset: <24 hours or same day as administration	34 (41.0)
Delayed-onset: ≥ 24 hours, ≥ 1 day following admission	26 (31.3)
Not reported/unassessable	23 (27.7)
Serious, n (%)*	54 (65.1)
Hospitalization	14
Life-threatening	9
Disability	1
Other	42
Causality assessment, n (%)	
Probable	16 (19.3)
Possible	67 (80.7)
* A case may have more than one serious outcome.	